Fibrosis is characterized by the excessive extracellular matrix deposition due to
dysregulated wound and connective tissue repair response. Multiple organs can develop …

Pharmacokinetics (PK) is the study of the absorption, distribution, metabolism, and excretion
(ADME) processes of a drug. Understanding PK properties is essential for drug development …

Farnesoid X receptor (FXR) is a promising target for nonalcoholic steatohepatitis (NASH)
and fibrosis. Although various FXR agonists have shown anti-fibrotic effects in diverse …

The NR superfamily comprises 48 transcription factors in humans that control a plethora of
gene network programs involved in a wide range of physiologic processes. This review will …

Nonalcoholic fatty liver disease, also called metabolic dysfunction‐associated steatotic liver
disease, is the most common liver disease worldwide and has no approved …

There is increasing evidence that maternal exposure to environmental pollutants can cause
intestinal and metabolic diseases, and these disease risks still exist in offspring. Here …

Farnesoid X receptor (FXR) is an important regulator of bile acid, lipid, amino acid, and
glucose homeostasis, hepatic inflammation, regeneration, and fibrosis. FXR has been …

Background Cholestasis is a clinical syndrome with high incidence and few effective
treatments. Oleanolic acid (OA) is a triterpenoid compound with anti-cholestatic effects …

Farnesoid X receptor (FXR) influences bile acid homeostasis and the progression of various
diseases. While the roles of hepatic and intestinal FXR in enterohepatic transport of bile …

Obeticholic acid (OCA), the first FXR-targeting drug, has been claimed effective in the
therapy of liver fibrosis. However, recent clinical trials indicated that OCA might not be …